



Acquisitions of own shares and Disposals of own shares

Brussels (Belgium), 20 April 2021 – 20:00 (CEST) – regulated information

Acquisitions of own shares

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV (“UCB” or the “Company”) (Euronext Brussels: UCB) hereby discloses certain information in relation to its Share Repurchase Program 2021.

Under this program, UCB has requested a financial intermediary to repurchase up to 750 000 UCB shares on its behalf under the terms of an initial discretionary mandate agreement with validity until 25 June 2021, effective as from 8 March 2021, to cover current and future obligations under UCB's Long Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2021, UCB repurchased 139 026 UCB shares on Euronext Brussels in the period from 9 April 2021 up to and including 19 April 2021, as follows:

Date of repurchase	Number of shares	Average Price Paid	Total	Lowest Price Paid	Highest Price Paid
09 April 2021	12.376	€ 80,94	€ 1.001.697,35	€ 80,68	€ 81,26
12 April 2021	33.516	€ 79,47	€ 2.663.395,86	€ 79,22	€ 80,64
13 April 2021	31.904	€ 78,83	€ 2.514.931,70	€ 78,20	€ 79,26
14 April 2021	19.138	€ 79,41	€ 1.519.731,36	€ 78,56	€ 79,92
15 April 2021	11.394	€ 80,66	€ 919.065,11	€ 79,40	€ 81,04
16 April 2021	18.736	€ 81,95	€ 1.535.426,44	€ 80,78	€ 82,24
19 April 2021	11.962	€ 83,06	€ 993.511,09	€ 82,24	€ 83,56

Disposals of own shares

For consistency reasons, UCB confirms that during the same period, it has not disposed of any UCB shares within the framework of the Long Term Incentive Program of the UCB Group.

This press release is available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: [@UCB_news](https://twitter.com/UCB_news)